SPECIAL REPORT
Long-term treatment with ofatumumab, a fully human anti-CD20 monoclonal antibody, is associated with a favourable safety profile and sustained efficacy, according to a newly-published analysis of the ALITHIOS long-term extension (Hauser et al. Mult Scler 2023; epublished September 11, 2023). The study is the most recent to support the earlier use of high-efficacy therapy in patients with multiple sclerosis. Read More
A new study has reported that the kappa free light chain index (K-index) can predict the occurrence of new T2 lesions in subjects with clinically isolated syndrome (CIS) and radiologically isolated syndrome (RIS) (Levraut et al. Neurol Neuroimmunol Neuroinflamm 2023;10:e200156). The K-index was also useful to predict clinical events in CIS. Read More
The TERIS trial of teriflunomide in individuals with radiologically isolated syndrome (RIS) has reported that treatment significantly prolonged the time to a first clinical event by 63% versus placebo (Lebrun-Frenay et al. JAMA Neurol, epublished August 21, 2023). Read More
The European Committee for Treatment and Research in MS (ECTRIMS) and the European Academy of Neurology (EAN) have published their first recommendations on vaccination in people with MS (Otero-Romero et al. Eur J Neurol 2023;30:2144-2176). The following is a summary of key recommendations for patients receiving higher-efficacy disease-modifying therapies (DMTs). Read More